Project Grant R01AG083628
Award Date
9/15/24
Completion Date
5/31/29
Dollars Obligated
$2.3M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Toledo, OH 43614, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $784,596 to Northeastern University to conduct comprehensive and cell type-specific proteogenomic profiling of aberrant and mis-processed proteins in Alzheimer's disease (AD) and tauopathy models. The project aims to substantially expand understanding of protein dysfunctions in AD by applying state-of-the-art proteomic methods paired with proteogenomics across multiple brain regions, AD stages,...
This $338,527 Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) supports research to understand the role of inhibitory interneurons in the pathophysiology of Alzheimer's disease (AD) and related dementias (ADRD). The key objectives are to: 1) Identify disrupted interneuron gene expression in post-mortem AD brain tissue, 2) Characterize inhibitory dysfunction in AD-derived induced interneurons in vitro, and 3) Assess the impact of transplanting healthy...
The National Institute on Aging (NIA) awarded a $619,681 Project Grant (CFDA 93.866 - Aging Research) to The Leland Stanford Junior University (Stanford University) to develop innovative tools for studying the complex genetic interactions underlying Alzheimer's disease (AD) pathogenesis. The project, titled "Combinatorial Perturbation with Multi-Omics Readout to Dissect Etiology of Alzheimer's Disease Using Stem Cell and In Vivo Models", will create a toolkit combining gene-editing...
The National Institute on Aging (NIA), under its Aging Research Federal Grant Program (CFDA 93.866), awarded a $4,622,818 Cooperative Agreement to investigate proteomic biomarkers for cognitive and brain changes prior to the onset of Alzheimer's disease and related dementias (AD/ADRD). The project will measure 7,000 proteins and established AD/ADRD biomarkers in the Lothian Birth Cohort 1936, a well-characterized longitudinal study, at ages 73, 76, 82, and 85. The research aims to identify...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support Emory University's research into the genetic regulation of brain transcriptomics and proteomics associated with Alzheimer's disease and related dementias. The $528,876 award, effective June 1, 2025, will fund the development of new analytic tools to integrate genomic data across multiple tissues and improve the identification of genetic risk factors and underlying molecular mechanisms for...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) will provide $3,772,856 to The University of Iowa to investigate the role of glycolysis, a key aspect of glucose metabolism, in Alzheimer's disease (AD) progression using rodent models. The research aims to better understand how disruptions in glycolysis contribute to neurodegeneration in AD, and explore whether improving glycolysis can mitigate disease symptoms. The award period runs from Sep 30, 2024...
This $6,226,692 project grant award from the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) will support research to examine the role of neuronal hyperexcitability and proteostasis (protein homeostasis) in the development of Alzheimer's disease (AD). The primary focus is on investigating how modifications in brain activity, particularly in the locus coeruleus (LC) and hippocampus (HPC) regions, can lead to the key pathological hallmarks of AD....
The National Institute on Aging (NIA) awarded a $842,175 Project Grant under the Aging Research program (CFDA 93.866) to the J. David Gladstone Institutes in San Francisco, CA. The grant, awarded on December 15, 2024, will fund research to explore the role of the NOX2 enzyme in mediating Alzheimer's disease (AD) pathologies, including network hyperactivity, glucose hypometabolism, and accumulation of amyloid-beta and tau proteins. The research aims to assess the therapeutic efficacy of a novel...
This Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $3,845,311 to the University of California, San Diego (UCSD) to investigate the early determinants of Alzheimer's disease (AD) using age-equivalent neurons derived from mild cognitive impairment (MCI) patients. The project aims to better understand the convergence of risk factors, including polygenic variants and biological aging, on molecular pathways that initiate and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to gain a mechanistic understanding of the role of cellular senescence in the pathogenesis of Alzheimer's disease (AD). The $460,625 grant will fund research at the University of Massachusetts Medical School to dissect the separate P53/P21 and P16 senescence pathways and their functional consequences in AD using human induced pluripotent stem cell-based models. The 2-year project will produce...